

## Table of Contents

<b>List of Tables</b> .....	<b>D-8</b>
<b>List of Figures</b> .....	<b>D-9</b>
<b>List of Abbreviations and Acronyms</b> .....	<b>D-10</b>
<b>Interagency Coordinating Committee on the Validation Of Alternative Methods: Agency Representatives</b> .....	<b>D-13</b>
<b>Acknowledgements</b> .....	<b>D-15</b>
<b>Preface</b> .....	<b>D-21</b>
<b>Executive Summary</b> .....	<b>D-23</b>
<b>1.0 Introduction and Rationale for the Proposed Use of the Reduced Murine Local Lymph Node Assay (rLLNA) to Identify Skin Sensitizers</b> .....	<b>D-27</b>
1.1 Introduction.....	D-27
1.1.1 Historical Background .....	D-27
1.1.2 Allergic Contact Dermatitis .....	D-27
1.1.3 U.S. Consumer Product Safety Commission (CPSC) Nomination .....	D-28
1.1.4 Description of the rLLNA .....	D-28
1.1.5 Results of an ECVAM Peer Review of the rLLNA .....	D-29
1.2 Regulatory Rationale and Applicability of the rLLNA .....	D-29
1.3 Scientific Basis for the rLLNA .....	D-29
1.3.1 Purpose and Mechanistic Basis .....	D-29
1.3.2 Applicability Domain.....	D-30
1.4 Test Method Validation .....	D-30
1.5 Selection of Citations for the rLLNA BRD .....	D-30
<b>2.0 rLLNA Protocol Components</b> .....	<b>D-31</b>
2.1 Overview.....	D-31
2.2 Basis for Test Method Selection .....	D-31
2.3 Proprietary Test Method Components .....	D-31
2.4 Basis for the Number of Mice per Dose Group .....	D-31
2.5 Study Acceptance Criteria .....	D-31
2.6 Basis for Selection of the Test Substance Dose.....	D-31

<b>3.0</b>	<b>Substances Used for Validation of the rLLNA .....</b>	<b>D-33</b>
3.1	Rationale for the Substances or Products Included in the Evaluation .....	D-33
3.2	Rationale for the Number of Substances Included in the Evaluation .....	D-33
3.3	Detailed Description of Substances Included in the Evaluation .....	D-33
3.4	Coding Procedures .....	D-35
<b>4.0</b>	<b>Comparative <i>In Vivo</i> Reference Data – the Traditional LLNA.....</b>	<b>D-37</b>
4.1	The Traditional LLNA Protocol Used to Generate Comparative <i>In Vivo</i> Reference Data.....	D-37
4.2	Comparative Traditional LLNA Reference Data Used .....	D-37
4.3	Availability of Original Records for Comparative Traditional LLNA Reference Data.....	D-37
4.4	Quality of Comparative Traditional LLNA Reference Data .....	D-37
4.5	Accuracy and Reliability of the Traditional LLNA.....	D-38
4.5.1	Accuracy .....	D-38
4.5.2	Reliability.....	D-38
<b>5.0</b>	<b>rLLNA Test Method Data and Results .....</b>	<b>D-39</b>
5.1	Description of the rLLNA Test Method Protocol Used to Generate Data ....	D-39
5.2	Availability of Original rLLNA Data Used to Evaluate Accuracy and Reliability.....	D-39
5.3	Description of the Statistical Procedure Used to Evaluate rLLNA Data.....	D-39
5.4	Summary of Results.....	D-39
5.5	Use of Coded Substances.....	D-40
5.6	Lot-to-Lot Consistency of Test Substances .....	D-40
5.7	Availability of Original Data for External Audit.....	D-40
<b>6.0</b>	<b>Accuracy of the rLLNA .....</b>	<b>D-41</b>
6.1	Performance Statistics .....	D-41
6.2	Discordant Results .....	D-43
<b>7.0</b>	<b>Reliability of the rLLNA.....</b>	<b>D-47</b>
<b>8.0</b>	<b>rLLNA Data Quality .....</b>	<b>D-49</b>
8.1	Adherence to National and International GLP Guidelines .....	D-49
8.2	Data Quality Audits .....	D-49
8.3	Impact of Deviations from GLP Guidelines .....	D-49
8.4	Availability of Laboratory Notebooks or Other Records .....	D-49

<b>9.0</b>	<b>Other rLLNA Scientific Reports and Reviews.....</b>	<b>D-51</b>
9.1	Reports in the Peer-Reviewed Literature.....	D-51
9.1.1	Ryan et al. (2008).....	D-51
<b>10.0</b>	<b>Animal Welfare Considerations.....</b>	<b>D-53</b>
10.1	How the rLLNA will Refine, Reduce, or Replace Animal Use.....	D-53
10.2	Requirements for the Use of Animals.....	D-53
<b>11.0</b>	<b>Practical Considerations.....</b>	<b>D-55</b>
11.1	Transferability of the rLLNA.....	D-55
11.2	rLLNA Training Considerations.....	D-55
11.3	Cost Considerations.....	D-55
11.4	Time Considerations.....	D-55
<b>12.0</b>	<b>References.....</b>	<b>D-57</b>
<b>13.0</b>	<b>Glossary.....</b>	<b>D-61</b>
<b>Annex I</b>	<b>ECVAM Scientific Advisory Committee Statement on the Validity of the rLLNA.....</b>	<b>D-65</b>
<b>Annex II</b>	<b>Physicochemical Properties of Substances Evaluated in the rLLNA .</b>	<b>D-71</b>
<b>Annex III</b>	<b>Traditional LLNA Data Used for the Performance Analysis of the rLLNA.....</b>	<b>D-109</b>
<b>Annex IV</b>	<b>Substances in the NICEATM LLNA Database for which an Initial Dose of 10% or Greater Elicited a Negative Result but a Subsequent Higher Dose Elicited a Positive Response.....</b>	<b>D-145</b>